Morphle Labs
Overview
Morphle Labs is a Bengaluru-based deep-tech healthcare startup founded in 2017 by Rohit Hiwale and Anchit Navelkar. The company specializes in the automation of cancer diagnostic processes through the integration of robotics, precision hardware, and AI technologies. With the recent Series A funding round of $5 million led by Inflexor Ventures, Morphle Labs aims to expand globally and scale manufacturing. The company has a growing presence in the US and Europe, with its flagship products, RoboTome and MorphoLens, already deployed in over 30 countries.
Recent Developments
- November 2025: Morphle Labs secured $5 million in a Series A funding round led by Inflexor Ventures. The funding is aimed at expanding global market reach, scaling manufacturing, and strengthening their IP portfolio. The investment emphasizes the company's focus on automating cancer diagnostics through its main offerings, RoboTome and MorphoLens.
- November 2025: The company announced plans to increase its manufacturing capabilities and pursue regulatory certifications necessary for medical device commercialization. RoboTome, a robotic microtome, and MorphoLens, an AI-driven imaging platform, are the primary focus areas for scaling efforts.
- 2025 Developments: Morphle Labs has filed over 80 patents across robotics and imaging technologies, highlighting its commitment to innovation and technology leadership within the healthcare sector. The company's expansion efforts are directed towards large markets in the United States and Europe.
- Global Operations: With operations in Bengaluru and Boston, Morphle Labs is expanding its team to enhance its capabilities in robotics, vision systems, optics, and compliance. This includes strategic hiring to support the development and deployment of its physical AI solutions.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2017 |
| Headquarters | Bengaluru, India |
| Founders | Rohit Hiwale, Anchit Navelkar |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Inflexor Ventures |
| Industry | Healthcare, Deep-tech, Automation |
| Number of Employees | Approximately 100 |
Early History
Morphle Labs started in 2017 with the vision to address critical workflow inefficiencies in cancer diagnostics through automation. The company was co-founded by Rohit Hiwale and Anchit Navelkar, who identified the unmet need in automating processes like histopathology, which remained manual and labor-intensive. Initially, the team focused on R&D to develop their proprietary technologies, leading to the creation of their flagship products, RoboTome, and MorphoLens. These products leverage robotics, precision hardware, and AI to automate diagnostic processes, thereby improving speed and accuracy.
Company Profile and Achievements
Morphle Labs is recognized for its innovations in the healthcare sector, specifically in cancer diagnostics. Its business model revolves around developing and deploying advanced robotic systems for the automation of tissue diagnostics.
- Product Innovations: RoboTome and MorphoLens are at the core of their offerings. RoboTome automates tissue slicing for microscopic examination, while MorphoLens facilitates high-resolution digital imaging.
- Technological Advancements: The company has filed for over 80 patents, reflecting its strong R&D focus.
- Market Expansion: Currently, Morphle Labs has a presence in over 30 countries, with significant installations across hospitals and diagnostic labs.
- Strategic Growth: The Series A funding will further enable the company to expand its manufacturing and accelerate regulatory approvals, thereby increasing its market footprint.
- Recognition and Partnerships: Morphle Labs' innovative approach has attracted attention from major investors and set new benchmarks in diagnostic automation.
Current Operations and Market Position
Morphle Labs operates at the intersection of healthcare and technology, focusing on automating tissue diagnostics. Its primary offerings, RoboTome and MorphoLens, address critical bottlenecks in histopathology by enhancing speed and precision in diagnostics. The company competes with medical device manufacturers globally but differentiates itself through its proprietary technologies and comprehensive automation solutions.
- Market Competitiveness: The company ranks 4th among its competitors in terms of active projects and technological innovation.
- Strategic Advantages: Advanced automation frameworks and a strong patent portfolio provide Morphle Labs with a competitive edge.
Conclusion
Morphle Labs is at the forefront of innovation in medical diagnostics, aiming to transform how cancer diagnostics are performed with its advanced automation technologies. As it expands operations globally and scales its manufacturing capabilities, Morphle Labs is poised to make significant contributions to the healthcare sector by reducing diagnostic bottlenecks and improving patient outcomes. The continued investment in R&D and global market expansion makes it a company to watch in the evolving landscape of healthcare automation.